Atlas Trials

A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT05590377 · TERMINATED

Trial details

NCT number
NCT05590377
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-01-23
Primary completion
2024-05-22
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.